Phone: 959-333-0983
Phone: 959-333-0983
Original price was: $144.99.$134.99Current price is: $134.99.
This item has been third-party tested by accredited U.S. laboratories and confirmed to meet a minimum purity of 98% through rigorous verification standards.
Original price was: $144.99.$134.99Current price is: $134.99.
Long-acting GHRH analog paired with a selective growth hormone secretagogue — two lyophilized peptides. Supplied by Research Chemical exclusively for laboratory research use.
CJC-1295 with DAC and Ipamorelin, lyophilized powders in sterile glass vials.
Independently analyzed by an accredited third-party lab.
Both peptides confirmed by mass spectrometry.
Supplied exclusively for laboratory investigation.
| Compound Class | Synthetic GHRH Analog with Drug Affinity Complex (DAC) |
|---|---|
| Form | Lyophilized powder, sterile glass vial |
| Amount per Vial | 5 mg |
| Sequence | Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH2, with a C-terminal Nε-maleimidopropionyl-lysine (DAC) extension |
| CAS Number | 863288-34-0 |
| Chemical Formula | C165H269N47O46 |
| Molar Mass | 3647.95 g/mol |
| Synonyms | CJC-1295 DAC, DAC:GRF, CJC-1295 with DAC |
| Verified Purity | Batch-tested to 98% (HPLC) |
| Compound Class | Synthetic Pentapeptide (Selective Growth Hormone Secretagogue / GHS-R Agonist) |
|---|---|
| Form | Lyophilized powder, sterile glass vial |
| Amount per Vial | 5 mg |
| Sequence | Aib-His-D-2-Nal-D-Phe-Lys-NH2 |
| CAS Number | 170851-70-4 |
| Chemical Formula | C38H49N9O5 |
| Molar Mass | 711.9 g/mol |
| Synonyms | Ipamorelin, NNC 26-0161 |
| Verified Purity | Batch-tested to 98% (HPLC) |
Each peptide batch is analyzed by an accredited third-party laboratory before it ships.
Every batch sold by Research Chemical is independently analyzed before it ships.
This product is an investigational compound and is not a drug, food, dietary supplement, or cosmetic. It is not approved for human or animal use, and it is unlawful to market it for that purpose.
Both CJC-1295 (a GHRH analog) and Ipamorelin (a growth hormone secretagogue) are prohibited by the World Anti-Doping Agency (WADA) at all times under S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics).
Research Chemical makes no representations regarding the safety or effects of this compound in humans or animals.
Research Chemical is a chemical supplier, not a medical provider. We do not condone or encourage consumer use of research compounds.
Research use only. All products sold by Research Chemical are intended exclusively for laboratory research and development. They are not for human or animal consumption. These statements have not been evaluated by the U.S. Food and Drug Administration, and these products are not intended to diagnose, treat, cure, or prevent any disease.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
1. Timms, M., Ganio, K., Forbes, G., Bailey, S., & Steel, R. (2019). An immuno polymerase chain reaction screen for the detection of CJC‐1295 and other growth‐hormone‐releasing hormone analogs in equine plasma. Drug testing and analysis, 11(6), 804-812
2. Teichman, S. L., Neale, A., Lawrence, B., Gagnon, C., Castaigne, J. P., & Frohman, L. A. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. The Journal of Clinical Endocrinology & Metabolism, 91(3), 799-805.
3. Sackmann-Sala, L., Ding, J., Frohman, L. A., & Kopchick, J. J. (2009). Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth Hormone & IGF Research, 19(6), 471-477.
4. Ionescu, M., & Frohman, L. A. (2006). Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. The Journal of Clinical Endocrinology & Metabolism, 91(12), 4792-4797.
5. Pinyot, A., Nikolovski, Z., Bosch, J., Such-Sanmartín, G., Kageyama, S., Segura, J., & Gutiérrez-Gallego, R. (2012). Growth hormone secretagogues: out of competition. Analytical and bioanalytical chemistry, 402, 1101-1108.
6. Campbell, R. M., Bongers, J., & Felix, A. M. (1995). Rational design, synthesis, and biological evaluation of novel growth hormone-releasing factor analogues. Biopolymers: Original Research on Biomolecules, 37(2), 67-88.
7. Campbell, R. M., Stricker, P., Miller, R., Bongers, J., Liu, W., Lambros, T., … & Heimer, E. P. (1994). Enhanced stability and potency of novel growth hormone-releasing factor (GRF) analogues derived from rodent and human GRF sequences. Peptides, 15(3), 489-495.
8. Teichman SL, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. The Journal of Clinical Endocrinology & Metabolism. 2006;91(3):799-805. doi: 10.1210/jc. 2005-1536.
9. Ionescu, M., & Frohman, L. A. (2006). Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. The Journal of Clinical Endocrinology & Metabolism, 91(12), 4792-4797.
10. Ma, X., Lin, L., Yue, J., Pradhan, G., Qin, G., Minze, L. J., … & Sun, Y. (2013). Ghrelin receptor regulates HFCS-induced adipose inflammation and insulin resistance. Nutrition & diabetes, 3(12), e99-e99.
11. Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective GH secretagogue. European Journal of Endocrinology. 1998 Oct;139(5):552-61. doi: 10.1530/eje.0.1390552.
12. Johansen, P. B., Nowak, J., Skjærbæk, C., Flyvbjerg, A., Andreassen, T. T., Wilken, M., & Ørskov, H. (1999). Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Growth Hormone & IGF Research, 9(2), 106-113.
13. Vahl, N., Juul, A., Jørgensen, J. O., Ørskov, H., Skakkebæk, N. E., & Christiansen, J. S. (2000). Continuation of GH replacement in GH-deficient patients during transition from childhood to adulthood: a two-year placebo-controlled study. The Journal of Clinical Endocrinology & Metabolism, 85(5), 1874-1881.
14. Sinha, D. K., Balasubramanian, A., Tatem, A. J., Rivera-Mirabal, J., Yu, J., Kovac, J., … & Lipshultz, L. I. (2020). Beyond the androgen receptor: the role of GH secretagogues in the modern management of body composition in hypogonadal males. Translational andrology and urology, 9(Suppl 2), S149.
15. Horvath, T. L., Castañeda, T., Tang-Christensen, M., Pagotto, U., & Tschop, M. H. (2003). Ghrelin as a potential anti-obesity target. Current Pharmaceutical Design, 9(17), 1383-1395.
16. Sjögren, K., Jansson, J. O., Isaksson, O. G., & Ohlsson, C. (2002). A model for tissue-specific inducible insulin-like growth factor-I (IGF-I) inactivation to determine the physiological role of liver-derived IGF-I. Endocrine, 19, 249-256.
17. D’Agostino, P. IGF-1 LR3: The rapid-acting GH alternative.
18. Ishida, J., Saitoh, M., Ebner, N., Springer, J., Anker, S. D., & von Haehling, S. (2020). Growth hormone secretagogues: history, mechanism of action, and clinical development. JCSM Rapid Communications, 3(1), 25-37.
19. Adeghate, E., & Ponery, A. S. (2004). Mechanism of ipamorelin-evoked insulin release from the pancreas of normal and diabetic rats. Neuroendocrinology Letters, 25(6), 403-406.
20. Andersen, N. B., Malmlöf, K., Johansen, P. B., Andreassen, T. T., Ørtoft, G., & Oxlund, H. (2001). The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats. Growth Hormone & IGF Research, 11(5), 266-272.
Please note that the above references provide evidence for the potential benefits of CJC 1295 DAC Peptide and Ipamorelin peptide as stated in the product description. For more in-depth information, kindly refer to these scholarly works.
Join our insider list for the latest research insights, product releases, and special offers—delivered straight to your inbox.